An Efficacy and Safety Study of AZD4831 (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD. - Trial NCT05492877
Access comprehensive clinical trial information for NCT05492877 through Pure Global AI's free database. This Phase 2 trial is sponsored by AstraZeneca and is currently Not yet recruiting. The study focuses on Chronic Obstructive Pulmonary Disease (COPD). Target enrollment is 288 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
AstraZeneca
Timeline & Enrollment
Phase 2
Nov 06, 2022
Apr 12, 2024
Primary Outcome
To evaluate the effect of AZD4831 as compared to placebo on the time to first COPD Composite Exacerbation (CompEx) event.
Summary
This is a research study to evaluate the efficacy and safety of the investigational drug
 AZD4831 in adult participants with chronic obstructive pulmonary disease.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05492877
Non-Device Trial